Cargando…
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338208/ https://www.ncbi.nlm.nih.gov/pubmed/35610531 http://dx.doi.org/10.1007/s40120-022-00363-7 |
_version_ | 1784759918191968256 |
---|---|
author | Collongues, Nicolas Becker, Guillaume Jolivel, Valérie Ayme-Dietrich, Estelle de Seze, Jérôme Binamé, Fabien Patte-Mensah, Christine Monassier, Laurent Mensah-Nyagan, Ayikoé Guy |
author_facet | Collongues, Nicolas Becker, Guillaume Jolivel, Valérie Ayme-Dietrich, Estelle de Seze, Jérôme Binamé, Fabien Patte-Mensah, Christine Monassier, Laurent Mensah-Nyagan, Ayikoé Guy |
author_sort | Collongues, Nicolas |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton’s tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS. |
format | Online Article Text |
id | pubmed-9338208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-93382082022-07-31 A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis Collongues, Nicolas Becker, Guillaume Jolivel, Valérie Ayme-Dietrich, Estelle de Seze, Jérôme Binamé, Fabien Patte-Mensah, Christine Monassier, Laurent Mensah-Nyagan, Ayikoé Guy Neurol Ther Review Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton’s tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS. Springer Healthcare 2022-05-24 /pmc/articles/PMC9338208/ /pubmed/35610531 http://dx.doi.org/10.1007/s40120-022-00363-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Collongues, Nicolas Becker, Guillaume Jolivel, Valérie Ayme-Dietrich, Estelle de Seze, Jérôme Binamé, Fabien Patte-Mensah, Christine Monassier, Laurent Mensah-Nyagan, Ayikoé Guy A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title | A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title_full | A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title_fullStr | A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title_full_unstemmed | A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title_short | A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis |
title_sort | narrative review on axonal neuroprotection in multiple sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338208/ https://www.ncbi.nlm.nih.gov/pubmed/35610531 http://dx.doi.org/10.1007/s40120-022-00363-7 |
work_keys_str_mv | AT collonguesnicolas anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT beckerguillaume anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT jolivelvalerie anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT aymedietrichestelle anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT desezejerome anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT binamefabien anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT pattemensahchristine anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT monassierlaurent anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT mensahnyaganayikoeguy anarrativereviewonaxonalneuroprotectioninmultiplesclerosis AT collonguesnicolas narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT beckerguillaume narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT jolivelvalerie narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT aymedietrichestelle narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT desezejerome narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT binamefabien narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT pattemensahchristine narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT monassierlaurent narrativereviewonaxonalneuroprotectioninmultiplesclerosis AT mensahnyaganayikoeguy narrativereviewonaxonalneuroprotectioninmultiplesclerosis |